Create New Share
Please enter the email address below of the person you would like to share this article with.
An email will be sent to the recipient with a link to this chosen article.
A source for healthcare professionals to access the latest data and information on the diagnosis, treatment and management of patients with gut related disorders
Oduyebo I & Camilleri M. Curr Opin Gastroenterol 2017;33:189–195.
Type 2 (primary) bile acid diarrhoea (BAD) is associated with increased bile acid production and occurs in nearly 30% of patients with diarrhoea-predominant irritable bowel syndrome (IBS-D). Primary BAD is associated with disorders of serum fibroblast growth factor 19 (FGF-19) which results in excess bile acid synthesis by hepatocytes. This leads to higher concentrations of bile acids in the colon and increased faecal bile acid loss.
The tauroselcholic (75selenium) acid (SeHCAT) test is the most commonly used test for the diagnosis of BAD. A retention of SeHCAT of less than 10% is indicative of moderate BAD; less than 5% retention suggests severe BAD. Measurement of fasting levels of FGF-19 may have diagnostic value; levels are lower in patients with BAD compared with diarrhoea controls.
Bile acid sequestrants provide symptom relief and are the treatment of choice for BAD. Patients will likely require long term therapy; tolerability is the main reason for discontinuation. A low-fat diet improves gastrointestinal symptoms when used alone in patients with mild BAD or in combination with bile acid sequestrants in patients with severe BAD.
Job number: JB57410GBw Date of Preparation: June 2019
You must be registered to GutNews.org
to view or download these files
Brief report: length of ileal resection correlates with severity of bile acid malabsorption in Crohn’s disease
In patients with Crohn’s disease who had a prior surgical resection there was a modest correlation between the length of ileal resection and the severity of bile acid malabsorption (BAM), as defined by tauroselcholic (75selenium) acid (SeHCAT) retention values. Response to bile salt sequestrant therapy was not dependent on SeHCAT retention values.
Are you a healthcare professional?
This educational website is developed by GE Healthcare for educational purposes. The information contained within this website is intended for healthcare professionals. By entering this website you are confirming that you are a healthcare professional.
This link opens another website that is not under the review or control of GE Healthcare Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.